Filed Date: Feb. 17, 2026
Case Ongoing
Clearinghouse coding in progress
(This summary is temporary, while we research the case.)
On February 17, 2026, The Endocrine Society filed this lawsuit against the Federal Trade Commission and its commissioners, alleging that the FTC launched an unlawful and retaliatory investigation to silence the Society’s speech about gender-affirming care. The complaint argued that the FTC’s Civil Investigative Demand targets the Society’s noncommercial, scientific speech—particularly its 2017 clinical practice guidelines on gender dysphoria—in violation of the First Amendment. Plaintiff alleged that the investigation was part of a broader Administration campaign to suppress what it calls “gender ideology,” including criticism of and pressure to retract the Society’s guidelines. They sought declaratory and injunctive relief to halt the FTC’s investigation and prevent further infringement of the Society’s constitutional rights.
This case is ongoing.
For PACER's information on parties and their attorneys, see: https://www.courtlistener.com/docket/72288700/parties/endocrine-society-v-federal-trade-commission/
Boasberg, James Emanuel (District of Columbia)
Tolentino, Raymond P. (District of Columbia)
See docket on RECAP: https://www.courtlistener.com/docket/72288700/endocrine-society-v-federal-trade-commission/
Last updated Feb. 19, 2026, 5:03 a.m.
State / Territory:
Case Type(s):
Special Collection(s):
Trump Administration 2.0: Challenges to the Government
Key Dates
Filing Date: Feb. 17, 2026
Case Ongoing: Yes
Case Details
Other Dockets:
District of District of Columbia 1:26-cv-00512
Available Documents: